Final overall survival results from the EORTC 1333/PEACE-3 trial: Enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology 2026 Open access

Read full text
Authors: E. Gallardo, Bertrand F. Tombal, Ananya Choudhury, Fred Saad, Andrey Coatrini Soares, Yohann Loriot, Raymond S. McDermott, Alejo Rodriguez-Vida, Pedro Isaacsson Velho, Felipe José Silva Melo Cruz, Thierry Andre Roumeguere, Gedske Daugaard
+6 more R. Yamamura, Frederic Lecouvet, Corneel Coens, C. Poncet, Béatrice Fournier, Silke Gillessen
DOI: 10.1200/jco.2026.44.7_suppl.15
Cited by: 2

Abstract

15 Background: In EORTC1333.PEACE-3 the combination of enzalutamide and radium-223 (ENZ/RAD) prolonged rPFS and OS (interim analysis) in patients with mCRPC with bone metastases, with a safety similar to that of each treatment alone, versus enzalutamide alone (ENZ). Here we report the final OS analysis an updated safety data. Methods: EORTC1333/PEACE-3 is a randomized, open-label, multicentre phase III trial evaluating the addition of radium-223 (ENZ/RAD) to enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC) with bone metastases. In PEACE-3, a total of 446 asymptomatic or mildly symptomatic patients (Brief Pain Inventory

Fields of Study & Subjects

Prostate Cancer Treatment and Research Radiopharmaceutical Chemistry and Applications Prostate Cancer Diagnosis and Treatment

Publication details

Journal / source
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Volume
44
Issue
7_suppl
Pages
15–15
Publication date
1 March 2026
Language
EN